ok so probably a dumb question but i keep seeing bits and pieces about the fda being stricter on glp-1
that shift to “being stricter” mostly translates to more demands for transparency and lot-specific data from compounding pharmacies. it’s not enough to see a general statement that a pharmacy does sterility testing as part of its process. you